Evidence map›Paper›PMID 25154607›Full record

Trial reportTrials2014

Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial.

Sung-Ji Park, Jin Joo Park, Dong-Ju Choi, Eun Ju Chun, Sang Il Choi, Sung Mok Kim, Shin Yi Jang, Soyeon Ahn, Yeon Hyeon Choe

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01769482 (Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01769482 phase4unknown statusnot on this map

Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image

TypeinterventionalSponsorSamsung Medical CenterRan2011 to 2014Enrolled70ConditionsMicrovascular AnginaArmsUdenafil, placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Current Diagnostic and Therapeutic Strategies in Microvascular Angina.Current emergency and hospital medicine reports · 2015
    Article
  4. Microvascular angina: angina that predominantly affects women.The Korean journal of internal medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sung-Ji Park
Jin Joo Park
Dong-Ju ChoiCardiovascular Center, Seoul National University Bundang Hospital, Internal Medicine, College of Medicine, Seoul National University, Gumiro 166, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Republic of Korea. djchoi@snu.ac.kr.
Eun Ju Chun
Sang Il Choi
Sung Mok Kim
Shin Yi Jang
Soyeon Ahn
Yeon Hyeon Choe
Seoul National University Bundang Hospital · KRSamsung Medical Center · KRSungkyunkwan University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrovascular angina (MVA) is characterized by anginal chest pain, an abnormal stress test, and normal coronary arteries on coronary angiography. Although the exact pathogenesis remains unclear, endothelial dysfunction is a contributing factor. To date, there exists no specific therapy for this disease. Phosphodiesterase-5 inhibitor improves the endothelial function and subsequently microvascular circulation. The aim of this study is to identify whether udenafil offers benefits in the treatment of MVA in female patients, who have a perfusion defect in their cardiac magnetic resonance image (CMR), but normal coronary arteries. METHODS/

designThe 'Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image: (UMPIRE)' trial is a multicenter, prospective, randomized, placebo controlled trial, designed to evaluate the effect of udenafil on myocardial ischemia and symptoms in female patients with MVA. The myocardial ischemia will be quantified by myocardial stress perfusion defect in CMR. A total of 80 patients with proven perfusion defect in adenosine-stress CMR will be randomly assigned to either the udenafil treatment group (daily dose of 100 mg) or the placebo group for three months. The primary endpoint is >25% improvement in perfusion defect size in adenosine-stress CMR from baseline. The secondary endpoints include <25% improvement in perfusion defect size, chest pain frequency, ST depression in stress test, Duke score in stress test, quality of life (QoL) assessment by SF-36 questionnaire, sexual dysfunction assessment by BISF-W (Brief Index of Sexual Functioning for Women) self-assessment questionnaire, and biomarkers for endothelial function. DISCUSSION: The UMPIRE trial is the first randomized controlled trial to evaluate the efficacy of udenafil in female MVA patients. If udenafil demonstrates cardioprotective effects, it may provide a novel therapeutic option to reduce myocardial ischemia and improve cardiac function in female MVA patients.

trial registrationClinical Trials.gov: NCT01769482 (registered on 20 November 2012).

Indexed as

Clinical ProtocolsMagnetic Resonance ImagingBenzenesulfonamidesChest PainDouble-Blind MethodFemaleHumansMyocardial Perfusion ImagingPhosphodiesterase 5 InhibitorsProspective StudiesPyrimidinesSample SizeSulfonamidesBenzenesulfonamidesPhosphodiesterase 5 InhibitorsPyrimidinesSulfonamidesudenafil

Identifiers

PMID25154607
PMCPMC4155115
OpenAlexW2116612445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.